SecBot SecBot
20-F ·Filed Nov 6, 2026

AVCRF

Avricore Health Inc.
BEARISH
Impact 6/10
Horizonmonths Processed10d 10h ago SEC0001493152-26-050516
Notable filing: 20-F
Actionable Insight ▼ Bearish

The UK pivot is the sole growth catalyst, but FY2025 financials show the company is in a cash-burning turnaround phase with no near-term path to profitability. Monitor the pace of UK HealthTab deployments, the Abbott collaboration ramp, and whether additional financing is needed before the UK revenue stream becomes material.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

BEARISH VIEWSTOCK AT ENTRY AT T+5
Entry
$0.000800
T+0 close · Nov 6, 2026 · via day close
Latest settled
0.00%
T+5 · $0.000800
Vs SPY
+1.69%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $0.000800entry
  2. T+1 · 7d ago 0.00%α +0.37% · $0.000800
  3. T+5 · 21h ago 0.00%α +1.69% · $0.000800
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Avricore Health's FY2025 20-F reports an 89% revenue decline to $533,884 after losing its major customer (Shoppers Drug Mart) on March 31, 2025. The company recorded a comprehensive loss of $1,858,840, took $493,544 in impairment charges on equipment and intangible assets, and ended the year with only $227,918 in cash. The auditor's report includes a going concern explanatory paragraph. The company is pivoting to the UK market, where it has deployed 38 HealthTab systems and signed a multi-year collaboration with Abbott, but the financial impact of this pivot is not yet material.

Key Facts

  • Revenue decreased 89% to $533,884 (FY2024: $4,785,711) due to the loss of the Shoppers Drug Mart contract on March 31, 2025
  • Gross profit fell 87% to $238,295 (FY2024: $1,880,287)
  • Comprehensive loss of $1,858,840 (FY2024: loss of $669,024)
  • Net cash used in operations of $789,933 (FY2024: cash provided by operations of $1,004,615)
  • Cash and cash equivalents fell to $227,918 (FY2024: $1,132,392)
  • Working capital dropped to $192,772 (FY2024: $1,252,139)
  • Impairment charges of $422,950 on equipment and $70,594 on intangible assets
  • Auditor's report includes a going concern explanatory paragraph citing recurring net losses and negative cash flows
  • 38 HealthTab systems operating in the UK as of December 1, 2025; UK revenue was $36,810
  • Post-period: closed a $1,254,000 private placement on June 16, 2026, issuing 25,080,000 units at $0.05 per unit
  • Accumulated deficit reached $34,263,284 at December 31, 2025

Financial Impact

Revenue declined by $4,251,827 (89% YoY); comprehensive loss increased by $1,189,816; cash burn of $904,295; impairments of $493,544

revenuegross profitnet losscash flow from operationscash and cash equivalentsworking capital

Risk Factors

  • Going concern risk: cash burn rate and minimal cash reserves raise substantial doubt about ability to continue operations without further financing
  • Customer concentration risk: the loss of Shoppers Drug Mart eliminated 87% of prior-year revenue with no replacement of comparable size
  • UK expansion execution risk: UK revenue was only $36,810 in FY2025, and scaling to replace lost Canadian revenue is unproven
  • Dilution risk: the post-period private placement added 25,080,000 shares (approximately 25% of pre-offering shares outstanding), with additional dilution possible from warrants

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 10 SEC documents filed with EDGAR.

DocumentAccession Number
20-F Filing (Primary)0001493152-26-050516
Exhibit: ex15b.htm0001493152-26-050516
Exhibit: ex15a.htm0001493152-26-050516
Exhibit: ex12-1.htm0001493152-26-050516
Exhibit: ex12-2.htm0001493152-26-050516
Exhibit: ex13-2.htm0001493152-26-050516
Exhibit: ex13-1.htm0001493152-26-050516
Document: 0001493152-26-050516-index-headers.html0001493152-26-050516
Document: 0001493152-26-050516-index.html0001493152-26-050516
Document: 0001493152-26-050516.txt0001493152-26-050516

Track record

4 reports on AVCRF

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today 6-K Neutral 3/10 Entry price pending
  2. Nov 6, 202610d ago 20-F Bearish 6/10 Viewing Entry $0.000800 to $0.000800 Now $0.000800 +0.00% · 0.00% −1.69% vs SPY
  3. Oct 9, 20265w ago 6-K Bullish 6/10 Entry $0.000800 to $0.000800 Now $0.000800 −0.00% · 0.00% +1.49% vs SPY
  4. Jul 10, 202618w ago 6-K Neutral 2/10 Entry $0.0332 to $0.0483 Now $0.000800 −97.59% ▲ +45.51% +46.46% vs SPY
Showing 4 of 4

US Market Status

Market Closed · Opens in 5h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026